Information  X 
Enter a valid email address

Company Name matching 'Sanofi'

Date
Time Source
Company
Announcement
08 Dec 2021 10:30 pm GNW   Sanofi - Aventis Groupe New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
01 Dec 2021 6:30 am GNW   Sanofi - Aventis Groupe Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
  6:00 am GNW   Sanofi - Aventis Groupe Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
18 Nov 2021 6:30 am GNW   Sanofi Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
09 Nov 2021 2:05 pm GNW   Sanofi Sanofi completes acquisition of Kadmon
28 Oct 2021 6:30 am GNW   Sanofi Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
25 Oct 2021 6:00 am GNW   Sanofi Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
22 Oct 2021 6:00 am GNW   Sanofi Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
20 Oct 2021 10:30 pm GNW   Sanofi FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
13 Oct 2021 8:00 am GNW   Sanofi New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 
30 Sep 2021 1:30 pm GNW   Sanofi New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
28 Sep 2021 7:00 am GNW   Sanofi Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
24 Sep 2021 6:30 am GNW   Sanofi Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
21 Sep 2021 6:00 am GNW   Sanofi New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
19 Sep 2021 4:30 pm GNW   Sanofi ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
14 Sep 2021 2:26 pm GNW   Sanofi Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
09 Sep 2021 6:00 am GNW   Sanofi Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
08 Sep 2021 6:00 am GNW   Sanofi Sanofi to acquire Kadmon to further strengthen growth of transplant business
30 Aug 2021 6:00 am GNW   Sanofi Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
06 Aug 2021 4:42 pm GNW   Sanofi FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
05 Aug 2021 11:00 am GNW   Sanofi Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
03 Aug 2021 6:00 am GNW   Sanofi Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
29 Jul 2021 5:24 pm GNW   Sanofi Online availability of Sanofi’s half-year financial report for 2021
  6:31 am GNW   Sanofi Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI
  6:30 am GNW   Sanofi Sales growth accelerated - Full-year guidance raised
  6:00 am GNW   Sanofi Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients  
13 Jul 2021 6:30 am GNW   Sanofi Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris
29 Jun 2021 9:00 am GNW   Sanofi Sanofi launches dedicated vaccines mRNA Center of Excellence
28 Jun 2021 7:00 am GNW   Sanofi Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
  6:00 am GNW   Sanofi Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
25 Jun 2021 6:30 am GNW   Sanofi Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
  6:15 am GNW   Sanofi Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
  6:00 am GNW   Sanofi Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
18 Jun 2021 2:45 pm GNW   Sanofi European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
11 Jun 2021 8:00 am GNW   Sanofi New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia 
07 Jun 2021 5:00 pm GNW   Sanofi Sanofi launches its new global employee share ownership plan
04 Jun 2021 6:00 am GNW   Sanofi Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
03 Jun 2021 1:00 pm GNW   Sanofi Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
01 Jun 2021 6:00 am GNW   Sanofi Sanofi provides update on venglustat clinical program
27 May 2021 6:30 am GNW   Sanofi Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
19 May 2021 10:45 pm GNW   Sanofi Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
  10:00 pm GNW   Sanofi Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
17 May 2021 3:00 pm GNW   Sanofi Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
  6:30 am GNW   Sanofi Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
06 May 2021 6:00 am GNW   Sanofi Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
30 Apr 2021 4:56 pm GNW   Sanofi Annual General Meeting of April 30, 2021
28 Apr 2021 6:30 am GNW   Sanofi Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
26 Apr 2021 7:00 am GNW   Sanofi Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
23 Apr 2021 3:05 pm GNW   Sanofi New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
19 Apr 2021 6:00 am GNW   Sanofi European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
12 Apr 2021 6:00 am GNW   Sanofi Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
09 Apr 2021 6:45 pm GNW   Sanofi Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
  5:01 am GNW   Sanofi Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
07 Apr 2021 8:03 am GNW   Sanofi Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
31 Mar 2021 10:15 pm GNW   Sanofi FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
  3:05 pm GNW   Sanofi Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
19 Mar 2021 6:30 am GNW   Sanofi Availability of the Q1 2021 Memorandum for modelling purposes
15 Mar 2021 6:00 am GNW   Sanofi Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival 
12 Mar 2021 6:00 am GNW   Sanofi Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
04 Mar 2021 5:18 pm GNW   Sanofi Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report


Company Announcements Archive »


a d v e r t i s e m e n t